The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
The breasts are principally composed of adipose, glandular, and connective tissues. Because these tissues have hormone receptors, their sizes and volumes fluctuate according to the hormonal changes particular to thelarche (sprouting of breasts), menstruation (egg production), pregnancy (reproduction), lactation (feeding of offspring), and menopause (end of menstruation).
The following outline is provided as an overview of and topical guide to diabetes mellitus (diabetes insipidus not included below): Diabetes mellitus – group of metabolic diseases in which a person has high blood sugar, either because the pancreas does not produce enough insulin, or because cells do not respond properly to the insulin that is produced, a condition called insulin resistance. The resultant high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger).
=== Reductive acetyl CoA pathway === The reductive acetyl CoA pathway (CoA) pathway, also known as the Wood-Ljungdahl pathway uses CO2 as electron acceptor and carbon source, and H2 as an electron donor to form acetic acid. This metabolism is widespread within the phylum Bacillota, especially in the Clostridia. The pathway is also used by methanogens, which are mainly Euryarchaeota, and several anaerobic chemolithoautotrophs, such as sulfate-reducing bacteria and archaea. It is probably performed also by the Brocadiales, an order of Planctomycetota that oxidize ammonia in anaerobic conditions. Hydrogenotrophic methanogenesis, which is only found in certain archaea and accounts for 80% of global methanogenesis, is also based on the reductive acetyl CoA pathway. The Carbon Monoxide Dehydrogenase/Acetyl-CoA Synthase is the oxygen-sensitive enzyme that permits the reduction of CO2 to CO and the synthesis of acetyl-CoA in several reactions. One branch of this pathway, the methyl branch, is similar but non-homologous between bacteria and archaea. In this branch happens the reduction of CO2 to a methyl residue bound to a cofactor. The intermediates are formate for bacteria and formyl-methanofuran for archaea, and also the carriers, tetrahydrofolate and tetrahydropterins respectively in bacteria and archaea, are different, such as the enzymes forming the cofactor-bound methyl group.
==== Bacterial ==== Syphilis: Bacterial infection which is usually sexually transmitted. It is caused by bacteria Treponema pallidum and it has different types of oral presentation at different stages of the disease.
Sources: en.wikipedia.org
28 February - 2 March In the Fourth Battle of Nakhang the PAVN 316th Division overran Royal Lao Army (RLA) forces at Lima Site 36 at Na Khang. The PAVN lost an estimated 250 killed and the RLA lost nine killed. The PAVN lost 26 killed while an entire RLA battalion was killed.
== History == Robert Guthrie is given much of the credit for pioneering the earliest screening for phenylketonuria in the late 1960s using a bacterial inhibition assay (BIA) to measure phenylalanine levels in blood samples obtained by pricking a newborn baby's heel on the second day of life on filter paper. Congenital hypothyroidism was the second disease widely added in the 1970s. Guthrie and colleagues also developed bacterial inhibition assays for the detection of maple syrup urine disease and classic galactosemia. The development of tandem mass spectrometry (MS/MS) screening in the early 1990s led to a large expansion of potentially detectable congenital metabolic diseases that can be identified by characteristic patterns of amino acids and acylcarnitines. In many regions, Guthrie's BIA has been replaced by MS/MS profiles, however the filter paper he developed is still used worldwide, and has allowed for the screening of millions of infants around the world each year. In the United States, the American College of Medical Genetics recommended a uniform panel of diseases that all infants born in every state should be screened for. They also developed an evidence-based review process for the addition of conditions in the future. The implementation of this panel across the United States meant all babies born would be screened for the same number of conditions. This recommendation is not binding for individual states, and some states may screen for disorders that are not included on this list of recommended disorders.
== Funding == Gavi runs in five-year funding cycles which enables it to negotiate long-term deals with vaccine manufacturers. Industrialised countries are Gavi's principal donors, providing approximately three-quarters of the total funding. All donor governments are represented on the Gavi Board through a constituency system (i.e. one donor country will represent several donors in their constituency). In the period of 2016–2020, Gavi received US$9.3 billion, with over half of the total funding provided by the three largest donors: the UK, the Bill & Melinda Gates Foundation (BMGF), and the USA (see table). Following the Global Vaccine Summit in June 2020 hosted in the UK, US$8.8 billion was raised for the funding cycle 2021 to 2025; exceeding the target of US$7.4 billion. This included US$2 billion from the UK, US$1.6 billion from the Gates Foundation and US$1 billion from Norway. For the 2026-2030 funding cycle, the UK announced it was committing to donate £1.25 billion (roughly US$1.7 billion), The Gates Foundation announced a US$1.6 billion contribution, and the US announced it was donating US$0. As a result, Gavi announced it would fall almost US$3 billion short of its budget aim of US$11.9 billion with a total budget of US$9 billion.
Sources: en.wikipedia.org
== F == Favorskii reaction Favorskii rearrangement Favorskii–Babayan synthesis Fehling test Feist–Benary synthesis Fenton reaction Ferrario–Ackermann reaction Ferrier carbocyclization Ferrier rearrangement Fétizon oxidation Fiesselmann thiophene synthesis Finkelstein reaction Fischer indole synthesis Fischer oxazole synthesis Fischer peptide synthesis Fischer phenylhydrazine and oxazone reaction Fischer glycosidation Fischer–Hepp rearrangement Fischer–Speier esterification Fischer Tropsch synthesis Fleming–Tamao oxidation Flood reaction Folin–Ciocalteu reagent Formox process Forster reaction Forster–Decker method Fowler process Franchimont reaction Frankland synthesis Frankland–Duppa reaction Fráter–Seebach alkylation Free radical halogenation Freund reaction Friedel–Crafts acylation Friedel–Crafts alkylation Friedländer synthesis Fries rearrangement Fritsch–Buttenberg–Wiechell rearrangement Fujimoto–Belleau reaction Fujiwara–Moritani reaction Fukuyama coupling Fukuyama indole synthesis Fukuyama reduction
== Side effects == Adverse drug reactions most commonly associated with loperamide are constipation (which occurs in 1.7–5.3% of users), dizziness (up to 1.4%), nausea (0.7–3.2%), and abdominal cramps (0.5–3.0%). Rare, but more serious, side effects include toxic megacolon, paralytic ileus, angioedema, anaphylaxis/allergic reactions, toxic epidermal necrolysis, Stevens–Johnson syndrome, erythema multiforme, urinary retention, and heat stroke. The most frequent symptoms of loperamide overdose are drowsiness, vomiting, and abdominal pain, or burning. High doses may result in heart problems such as abnormal heart rhythms.
Trump nevertheless urged his supporters on January 6 to march to the Capitol while the joint session of Congress was assembled there to count electoral votes and formalize Biden's victory, whereupon hundreds of people stormed the building and interrupted the count. During the attack, Biden addressed the nation, calling the events "an unprecedented assault unlike anything we've seen in modern times". After the Capitol was cleared, Congress officially counted the election results, with Pence, in his role as president of the Senate, announcing Biden and Harris as the winners. On January 7, Trump acknowledged the incoming administration without mentioning Biden's name.
=== Data breaches and COVID-19 impact (2020–present) === Because of the COVID-19 impact, PGCPS schools went through lockdown after March 13, 2020. The 2020–21 school year was online during the year until April 2021 with hybrid learning. The 2021–22 was virtual for some and in-person for some. Because of COVID-19 cases increasing during late 2021, PGCPS went through online school mode again until January 18, 2022 for in-person students and January 31, 2022 for virtual students to go to in-person school. On August 14, 2023, PGCPS experienced a data breach which caused all students and staff to be locked out of their accounts. Students had to reset their password during the week of August 28, while staff had to reset it immediately. PGCPS were able to regain control of their systems within 12 hours, and sent a message to every student in the district about the cyber attack. Starting from the 2023–24 school year, clear backpacks are required for high school students and Non Traditional Program North, South and Middle and optional for middle school students to combat shooting in the district.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.